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TetraspanTransmembrane 4 L six family member 5 (TM4SF5) causes epithelial–mesenchymal transition (EMT) for
aberrant cell proliferation. However, the effects of TM4SF5 expression on cell cycle are unknown so far. In
this study, using hepatocytes that either ectopically or endogenously express TM4SF5 and human
hepatocarcinoma tissues, the role of TM4SF5 in G1/S phase progression was examined. We found that
TM4SF5 expression accelerated G1/S phase progression with facilitated cyclin D1 and E expression and Rb
phosphorylation. Furthermore, TM4SF5 enhanced trafﬁcking of CDK4 and cyclin D1 into the nucleus and
induced complex formation between them. However, TM4SF5-facilitated G1/S phase progression was
blocked by silencing of p27Kip1 using siRNA or by infection of active RhoA. Pharmacological inhibition of
ROCK accelerated the G1/S phase progression of control TM4SF5-unexpressing cells. Altogether, these
observations suggest that TM4SF5 accelerates G1/S phase progression with facilitated CDK4/cyclin D1 entry
into the nucleus, which might be supported by TM4SF5-mediated actin reorganization through cytosolic
p27Kip1 expression and Rho GTPase activity.search Institute of Pharmaceu-
search Center, Seoul National
, Korea. Tel.: +82 2 880 2495;
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
Tumor cells grow by exploiting their microenvironment, which
contains various extracellular matrices, soluble factors and neighbor-
ing cells [1–5]. For such processes to occur, cell membrane receptors
sense extracellular cues and transduce intracellular signaling path-
ways [6]. Cell–cell adhesion via E-cadherin and cell–extracellular
matrix (ECM) protein adhesion via integrins can be important for the
architectural integrity of normal epithelium and for sensing extracel-
lular cues [7]. During tumor metastasis, epithelial cell adhesions may
be disturbed, leading to mesenchymal cell type transition (i.e.,
epithelial–mesenchymal transition, EMT) [8]. Tumor cells also show
uncontrolled growth [9]. It is likely that cancer cells undergoing EMT
may be unable to sense neighboring cells, leading to growth in a
multilayered pattern after losing contact inhibition as long as they
keep continual cell cycle progression.TM4SF5 forms a transmembrane 4 L six family together with L6
(tumor-associated antigen TM4SF1 or L6-Ag), IL-TMP, and L6D [10].
TM4SF5 is highly expressed in diverse tumor types [11,12] including
hepatocarcinoma [13] and colon carcinoma (S.-A. Lee and J.W. Lee,
unpublished data). As tetraspanins have both homo- and heterophilic
interactions that likely organize the tetraspanin-enriched microdo-
main (TERM) on cell surfaces [14], TM4SF5 also interacts with
integrins to regulate actin reorganization, cell adhesion, spreading,
migration and gene expression [15–17]. In addition, TM4SF5
expression in epithelial cells leads to stabilization of p27Kip1 in the
cytosol and inactivation of RhoA, resulting in aberrant actin
reorganization that causes EMT and loss of contact inhibition for
anchorage-independent growth [13], although how TM4SF5 affects
cell cycle progression itself is not known.
Cells progressing from G1 to S phase overcome the restriction (R)
point where the cyclin D/CDK4/6 complex is activated and phos-
phorylates Rb to induce S phase cyclin E via the E2F transcription
factor [18]. Certain tumor cells may have efﬁcient capacities to pass
through the R point to facilitate DNA synthesis and cell division, which
may eventually lead to a shortening of G1 or an acceleration of G1/S
progression during anchorage-independent, uncontrolled cell prolif-
eration [19,20].
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progression. We hypothesized that TM4SF5 expression affects cells'
capacity to progress cell cycle phases or facilitate cell cycle
progression, since TM4SF5 expression causes EMT and multilayer
growth [13], for which the TM4SF5-expressing cells may still maintain
the cell cycle progression capacity enough to grow in multilayer. We
observed that TM4SF5 expression facilitated cyclin D1 induction and
CDK4/cyclin D1 entry into the nucleus, leading to accelerated G1/S
phase progression. Furthermore, we noted that TM4SF5-mediated
cytosolic p27Kip1 expression and RhoA inactivation correlated with
the acceleration of S phase entry.
2. Materials and methods
2.1. Cells
Parental SNU449 hepatocellular carcinoma lacking TM4SF5 (Ko-
rean Cell Bank) was infected with control retrovirus (SNU449Cp) or
TM4SF5-retrovirus (SNU449Tp), as previously described [13]. Huh7,
HepG2 hepatocytes endogenously expressing TM4SF5, Cos7, and
HEK293 cells (ATCC, [13]) were maintained in DMEM-H (WelGENE
Inc., Daegu, Korea).
2.2. Western blots
Cells in normal RPMI-1640 media plus 10% FBS (WelGENE Inc.)
were harvested, as previously described [13]. Alternatively, cells were
serum-starved for 24 h without or with control siRNA or p27Kip1
siRNA adenovirus, control or active RhoA (63L, a kind gift from Dr.
Christopher S. Chen, Univ. of Pennsylvania) adenovirus, vehicle PBS or
Y27632 (Calbiochem) treatment at the indicated concentrations, prior
to incubation with 10% FBS-containing media for the indicated time.
After incubation, cells were harvested for standard Western blots.
Whole cell lysates were prepared using modiﬁed RIPA buffer [13].
Protein levels were analyzed and normalized using the BCA method
(Pierce), and immunoblots were performed using anti-cyclin D1,
cyclin E, CDK4, p16, p18, phospho-Ser10p27Kip1, Myc, EGFR, phospho-
Tyr1173EGFR, β-catenin (Santa Cruz Biotech.), α-tubulin (Sigma),
phospho-Tyr, active-EGFR, RhoA, p27Kip1 (BD Transduct. Lab.),
phospho-Thr157p27Kip1 (R & D Systems), Rb, phospho-Ser807Rb
(Genscript), lamin B1 (Invitrogen), Erk1/2, and phospho-Erk1/2
(Cell Signaling).
2.3. Flow cytometry analysis
Cells were serum-starved for 24 h in serum-free RPMI-1640,
before incubation with 10% FBS-containing RPMI-1640 for the
indicated times. In certain cases, cells were infected with adenovirus
for control or siRNA against p27Kip1, active RhoA (63 L), or treated
with vehicle or 15 µM Y27632, during serum starvation for 24 h. After
incubation, cells were harvested for cell cycle analysis with propidium
iodide staining, as explained previously [21]. The percentages for cell
cycle phases for each experimental condition were calculated via
ModFit software and plotted.
2.4. Cytoplasmic and nuclear protein extraction
Cytosolic and nuclear fractionation from control SNU449Cp and
TM4SF5-expressing SNU449Tp cells was performed, as described
previously [22].
2.5. Cyclin D1 promoter assay
An insert of promoter region (−1450) of Cyclin D1 (GeneBank
S78335) with a reporter luciferase gene [23] was ampliﬁed by PCR
using a 5′ linker for Mlu I and a 3′ linker for Bgl II to be inserted intopGL3-basic (Promega). Cos7 and HEK293 cells were cotransfected
with pGL3-cyclin D1 promoter, pBabe-β-galactosidase, and control
myc-(His)6 or different amounts of myc-(His)6-TM4SF5 vector for
24 h. Control vector was used to normalize for DNA. Luciferase activity
was normalized for the transfection efﬁciency using β-galactosidase
activity.
2.6. Immunoprecipitation
Coimmunoprecipitation between CDK4 and cyclin D1 was per-
formed using whole cell lysates from subconﬂuent SNU449Cp and
SNU449Tp cells, as explained previously [24].
2.7. Immunoﬂuorescence microscopy
Cells on cover glasses precoated with 10% FBS-containing normal
culture media were serum-starved for 24 h, prior to incubation with
the normal culture media for the indicated times. The cells on cover
glasses were ﬁxed and processed for immunoﬂuorescent staining
using anti-CDK4 or cyclin D1 antibody (Santa Cruz Biotech.), as
described previously [15]. Mounted samples were visualized by
ﬂuorescent microscopy (BX51, Olympus). Cells with CDK4 or cyclin
D1 in the nucleus, peri-nucleus or cytosol were counted by two
independent individuals on at least ﬁve random images to obtain
mean±standard deviation values.
2.8. Human liver tissue sample
Normal and tumor liver tissues were obtained from patients in the
Kyungpook National University Hospital (Daegu, Korea) from March
to April, 2007 with informed consent and IRB agreement (2007-007).
Clinical and biological information was available for the tissue
samples. Tissue extracts were prepared in modiﬁed RIPA buffer,
normalized, and used for standard Western blots. Alternatively, serial
sections (6 μm thick) cut from each parafﬁn block were stained for
cyclin D1 (1:100, Santa Cruz Biotech.), prior to microscopic visuali-
zation (BX51, Olympus).
2.9. Statistical methods
Student's t-tests were performed for comparisons of mean values
to determine if differences were signiﬁcant. p values≤0.05 were
considered signiﬁcant.
Supplementary ﬁgures are included at the web site of BBA-
Molecular Cell Research.
3. Results
3.1. TM4SF5 accelerates G1/S phase progression
Although the roles of TM4SF5 in diverse cellular functions [13,15–
17] have been reported, the roles of TM4SF5 in the cell cycle remain
unknown. We thus explored the effects of TM4SF5 on the cell cycle.
Control TM4SF5-null SNU449Cp and -expressing SNU449Tp cells
were serum-starved for 24 h before incubation in 10% FBS-containing
normal culture media. At various times after 10% FBS application, cell
populations in each phase of the cell cycle were examined by ﬂow
cytometry analysis (Fig. 1A). Interestingly, SNU449Cp cells showed a
slow entry into S phase to a slight degree (∼30%) with a peak of S
phase around 24 h after 10% FBS application, whereas SNU449Tp cells
showed a dramatic (∼70%) entry into S phase 18 h after 10% FBS
application (Fig. 1B). Although the cells were serum-starved for 24 h,
the cells showed a slightly higher S phase population (∼20%) at the
t=0 condition and slightly higher S to G2/M transitions at t=6 h,
indicating an autocrine effect during the long 24 h starvation (Fig. 1B).
During serum starvation, cell death was negligible (data not shown).
Fig. 1. TM4SF5 accelerated G1/S phase progression. (A) SNU449Cp (449Cp) and SNU449Tp (449Tp) cells were serum-starved for 24 h, prior to incubation with 10% FBS-containing
RPMI-1640 additionally for the indicated times. After incubation, cells were harvested andmixed with propidium iodide for ﬂow cytometry to analyze cell cycle population. The data
set shown is the representative set out of 3 independent experiments. (B) Graphic presentation of the set in (A). Triangle, G1 phase; rectangle, S phase; circle, G2/M phase,
SNU449Cp; open symbols, SNU449Tp; closed symbols.
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approximately 30% of cells at t=12 h with a decrease in G2/M phase,
consequently reaching 70% of cells in S phase at t=18 h, whereas
SNU449Cp cells reached approximately 20% and 30% of cells in S phase
at t=18 and 24 h, respectively (Fig. 1). Therefore, these cell cycle
population patterns indicate that TM4SF5 expression may accelerate
and potentiate G1/S phase progression.
3.2. TM4SF5 expression enhances biochemical processes to pass the G1
restriction point
Since cell cycle progression to S phase involves expression of cyclin
D, phosphorylation of Rb, and eventually expression of cyclin E [18], we
examined whether TM4SF5 expression might also facilitate the
necessary biochemical events for accelerated S phase entry. TM4SF5-
expressing SNU449Tp cells showed a higher basal cyclin D1 expression
levels, compared to control SNU449Cp cells (Fig. 2A, lanes 1 and 2, left
panel). After application of 10% FBS-containing culturemedia, cyclin D1
levels in SNU449Tp cells further increased and remained consistently
higher up to 12 h after serum application, whereas SNU449Cp cells
showed insigniﬁcant levelswith a slight and transient increase (Fig. 2A).
Correlating with expression of basal and serum-enhanced cyclin D1 inSNU449Tp cells, TM4SF5 transfection into TM4SF5-null cells resulted in
enhanced cyclin D1 promoter activity, although this enhancement was
much more obvious in ﬁbroblasts than in SNU449 cells with an
approximate 2-fold increase (Fig. 2B). Furthermore, SNU449Tp cells
showed higher basal and serum-enhanced Rb phosphorylation (pS807-
Rb) compared to control SNU449Cp cells (Fig. 2C), indicating facilitated
progression through the restriction (R) point in SNU449Tp cells.
Similarly, SNU449Tp cells showed slightly higher basal and dramatically
serum-enhanced cyclin E levels (Fig. 2D). All these biochemical events
facilitated in SNU449Tp cells under both basal and serum-stimulated
conditions indicate that TM4SF5 expression can facilitate G1/S phase
progression through the R point.
3.3. The TM4SF5-mediated effects do not involve growth factor-mediated
Erk activation
Progression from G1/S phase in a serum-dependent manner can
be modulated by activation of growth factor-mediated receptors and
thereby Erk1/2 [25]. Therefore, we examined phosphorylation of
growth factor receptors (∼170 kDa) and Erk1/2 in SNU449Cp and
SNU449Tp cells. Unlike the higher cyclin D1 levels observed under
basal and serum-stimulated conditions of SNU449Tp cells, phospho-
Fig. 2. TM4SF5 expression facilitated cyclin D1 expression, Rb phosphorylation, and cyclin E expression. (A, C, and D) SNU449Cp and SNU449Tp cells were serum-starved for 24 h,
before incubation with the culture media plus 10% FBS for the indicated periods. After incubation, cells were harvested using a modiﬁed RIPA buffer, prior to the standard Western
blots using antibodies against the indicated molecules. (B) SNU449, HEK293, or COS7 cells were transfected with−1450 Cyclin D1 promoter-luciferase, pBabe-β-galactosidase, and
control myc-(His)6 or different amounts of myc-(His)6-TM4SF5 vector for 24 h. Control vector was used to compensate the DNA amount. Luciferase activity analyzedwas normalized
using β-galactosidase activity for the transfection efﬁciency. Note that SNU449 cells show ∼2 fold increase in cyclin D1 promoter activation by TM4SF5, but other cells show much
more fold increases. Data shown represents three independent experiments.
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Erk1/2) in both cell lines were similar under basal conditions and
similarly increased by serum stimulation (Fig. 3A). In addition, the
expression levels of β-catenin and myc, which correlate with cyclin
D1 expression [26,27], did not correlate with cyclin D1 levels
(Supplementary Fig. 1a). Therefore, these observations suggest that
TM4SF5 uniquely accelerates G1/S phase progression independently
on growth factor receptor-mediated Erk1/2 activation and other
cyclin D1 regulators (such as β-catenin and myc) expressions. To
avoid possible clonal differences among stable cells, we examined
other stable TM4SF5-positive cell lines (single cell driven SNU449T7
and SNU449T16 clones) at diverse time points after serum applica-
tion. Even 30 min after serum application, SNU449T7 and SNU449T16
cells showed higher cyclin D1 levels than SNU449Cp cells, although pY
around 170 kDa and pErk1/2 did not correlate with the cyclins
(Fig. 3B). However, TM4SF5-expressing cells showed an obvious and
dramatic increase in cyclin E expression, after serum stimulation,
whereas control TM4SF5-null cells showed a very slow increase in
cyclin E expression to a lesser level (Fig. 3B), indicating TM4SF5-
mediated facilitation of S phase entry. We next investigated whether
hepatocarcinoma (HCC) tissues express higher levels of cyclin D1.
Using tissues from HCC patients, we found that HCC tissues expressed
higher cyclin D1 levels, compared to normal tissues (Fig. 3C).
Furthermore, tissue extracts were immunoblotted for cell cycle-
related molecules and signaling activities. Tumor tissues showed
higher cyclin D1 levels, but levels of p16 and p18 cyclin-dependent
kinase inhibitors were not higher in tumor tissues, indicating that
certain cell cycle progression characteristics may be unique in
TM4SF5-positive HCC tissues (Fig. 3D). Correlated with the observa-tions from in vitro cell systems, tissue extracts did not show any
correlation between cyclin D1 and growth factor receptor (especially
EGFR) phosphorylation or pErk1/2 levels (Fig. 3D). In addition,
enhanced cyclin D1 levels in HCC tissues did not correlate with β-
catenin and myc levels (Supplementary Fig. 1b). Therefore, as shown
in both cellular and tissue systems, TM4SF5 expressionmight lead to a
unique enhancement of cyclins D1 and E expression levels and Rb
phosphorylation independent on EGFR-mediated Erk1/2 activation,
β-catenin, or myc proteins.
3.4. TM4SF5 facilitates translocation of CDK4 and cyclinD1 into the nucleus
In addition to enhanced expression levels of cyclin D1, TM4SF5
expression resulted in cytosolic p27Kip1 stabilization and RhoA
inactivation [13], leading to actin reorganization [15] and presumably
intracellular contractility changes [28]. Intracellular contractility has
been shown to affect nuclear gene expression, depending on
contractility-dependent trafﬁcking of molecules and complex forma-
tion [29]. We thus wondered whether enhanced expression of basal
and serum-stimulated cyclin D1 in SNU449Tp cells might be due to
facilitated translocation of CDK4/6 and cyclin D1 into the nucleus,
where complex formation of both could induce Rb phosphorylation
[30]. When subcellular localization of CDK4 was examined at various
time points after serum stimulation of serum-starved cells, SNU449Tp
cells showed a more dramatic increase in the population of cells with
nuclear CDK4 compared to SNU449Cp cells (Fig. 4A and Supplemen-
tary Fig. 2). Meanwhile, the number of cells with cytosolic CDK4
decreased with time after serum stimulation of SNU449Tp cells, but
not of SNU449Cp cells (Fig. 4A). We next investigated the localization
Fig. 3. TM4SF5-mediated effects were not due to growth factor receptor-mediated Erk1/2 signaling pathway. (A and B) Control TM4SF5-nonexpressing SNU449Cp (Cp) and
TM4SF5-expressing SNU449Tp, SNU449T7 (T7), or SNU449T16 (T16) cells were manipulated as in Fig. 2A, prior to standard Western blots for the indicated molecules. pErk1/2 blot
was slightly exposured for cleaner bands at 30 min and thus their enhancements 6 h after serum treatment were not obvious, although pErk1/2 were increased 1 to 5 h after serum
treatment, as shown in (A). (C and D) Human hepatocarcinoma tissues (T) and counter normal tissues (N) were processed for either immunohistochemistry against cyclin D1, as
explained in the Materials and methods (C), or standard Western blots for the indicated molecules (D). Data shown represents three independent experiments.
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at various times after serum stimulation. Similar to CDK4, cyclin D1
nuclear localization was higher in SNU449Tp cells than in SNU449Cp
cells (Fig. 4B and Supplementary Fig. 3). To determine biochemically
whether the localization of cell cycle-related molecules might be
different depending on TM4SF5 expression levels and correlated with
TM4SF5-enhanced nuclear cyclin D1, we separated cell extracts into
cytosolic and nuclear fractions. Interestingly, cyclins D1 and E were
much higher in the nuclei of SNU449Tp cells under basal and serum-
stimulated conditions, whereas p27Kip1 was accumulated in the
cytosol of SNU449Tp cells (Fig. 4C). Cyclin D1 associated with CDK4
in the nucleus (Fig. 4D) to presumably induce Rb phosphorylation.
Therefore, TM4SF5 expression appeared to facilitate CDK4/cyclin D1
translocation into the nucleus, in addition to the previous observation
that TM4SF5 caused cytosolic p27Kip1 stabilization and RhoA inacti-
vation [13].
3.5. Cytosolic p27Kip1 level and RhoA activity are involved in the
TM4SF5-mediated acceleration of G1/S phase progression
Since our observations suggest possible roles of cytosolic p27Kip1 and
RhoA in the TM4SF5 effects on G1/S progression, we examined whether
regulation of cytosolic p27Kip1 levels using siRNA or regulation of the
RhoA/ROCK signaling pathway may block the TM4SF5-mediated accel-
eration of G1/S phase progression. First, we assessedwhether silencing of
p27Kip1 in SNU449Tp cells might decrease cyclin D1 expression levels.
Compared to control SNU449Cp cells or control siRNA-adenovirus-
infected SNU449Tp cells, suppression of p27Kip1 in SNU449Tp cells
decreased cyclins D1 and E expression and pS807-Rb levels in a dose-
dependent manner (Fig. 5A). More directly, we tested the effects of
p27Kip1 suppression on cell cycle populations at various time points after
serum treatment of serum-starved cells. Cells were infected with controlsiRNA or sip27Kip1 adenovirus for 24 h, serum-starved for another 24 h,
and then incubated with 10% FBS-containing culture media for the
indicated times prior to harvest for ﬂow cytometry analysis. Twelve to
18 h after serum stimulation (i.e., the time to show dramatic G1/S phase
progression as shown in Fig. 1), the serum-mediated increase in the S
phase population of SNU449Tp cellswas partially inhibited and cells inG1
phase less declined after infection with adenovirus-sip27Kip1 (Fig. 5B),
indicating that suppression of p27Kip1 (mostly located in cytosol [13])
resulted in a decelerated progression into S phase.
Furthermore, we then tested whether activation of RhoA in
SNU449Tp cells (which has inactive RhoA [13]) might lead to retarded
entry into S phase. Expression of active RhoA (RhoA 63L) in SNU449Tp
cells via adenovirus infection resulted in decreases in cyclins D1 and E
expression and pS807-Rb levels (Fig. 6A). In addition, compared to cells
infected with control adenovirus, infection of SNU449Tp cells with
adenovirus for active RhoA caused less progression into S phase 15 h
after serum stimulation, whereas cells in G1 phase showed a lesser
decrease (Fig. 6B). Meanwhile, inactivation of ROCK (a RhoA
downstream effector) in TM4SF5-null SNU449Cp cells using the
Y27632 pharmacological inhibitor resulted in induction of cyclins D1
and E (Fig. 6C, top). Furthermore, ROCK inhibition in serum-starved
SNU449Cp cells increased cyclin D1 expression (Fig. 6C, bottom, lanes
1 and 2), which is reminiscent of SNU449Tp cells that showed a lower
RhoA activity [13] and a higher basal cyclin D1 level (Fig. 2A).
Meanwhile, 10% FBS treatment slightly increased cyclin D1 (Fig. 6C,
bottom, lanes 1 and 3) and ROCK inhibition of serum-treated cells
more increased cyclin D1 expression (Fig. 6C), indicating that ROCK
inactivation may facilitate cyclin D1 expression. G1/S phase progres-
sion was also facilitated after ROCK inhibition in TM4SF5-null
SNU449Cp cells; G1 phase population rapidly decreased and concom-
itantly S phase population increased, as time passed after serum
treatment (Fig. 6D).
Fig. 4. TM4SF5 expression facilitated translocation of CDK4 and cyclin D1 into the nucleus. SNU449Cp (Cp) and SNU449Tp (Tp) cells were manipulated as in Fig. 2A, prior to
immunostaining for CDK4 (A) or cyclin D1 (B), standard Western blots for the indicated molecules using nucleus or cytosol fractions, as described in the Materials and methods (C),
or coimmunoprecipitation using anti-CDK4 antibody followed by immunoblotting for cyclin D1 (D). Note that different degrees of p27Kip1, pT157p27Kip1, cyclin D, and CDK4
migration on gels may be attributed to diverse posttranslational modiﬁcations. Data shown represents three independent experiments.
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When normal cells contact each other (i.e., become conﬂuent), they
stop proliferating, which is known as contact inhibition. However,
tumor cells may grow in a multilayer pattern, as long as they progress
through the cell cycle efﬁciently even under conﬂuent conditions. It was
previously reported that TM4SF5 causes epithelial-mesenchymal
transition (EMT) and multilayer growth [13]. However, the effects of
TM4SF5 expression on cell cycle progression are unknown.
This study shows that TM4SF5 expression accelerates G1/S phase
progression by facilitating passage through the G1 restriction (R)
point. The facilitated passage through the R point was shown by
TM4SF5-dependent cyclins D1 and E expression and Rb phosphor-
ylation, which correlated with efﬁcient translocation of and complex
formation between CDK4 and cyclin D1 in the nucleus and induction
of Rb phosphorylation. Furthermore, TM4SF5-enhanced translocation
of CDK4/cyclin D1 into the nucleus depended on p27Kip1 expression
levels and RhoA/ROCK signaling activity. It is thus likely that
TM4SF5-mediated cytosolic p27Kip1 stabilization and RhoA activity,
which led to the regulation of actin reorganization [13], would
somehow enhance trafﬁcking of CDK4/cyclin D1 into the nucleus for
Rb phosphorylation, cyclin E induction, and accelerated G1/S
progression. Cyclin D translocation in normal cells is known to be
regulated by a signaling cascade including PI3K/Akt [31]. Compared
to no TM4SF5-expressing control cells, Akt is highly activated inhepatocytes overexpressing TM4SF5 presumably to cause Ser10
phosphorylation of p27Kip1 for cytosolic translocation [13]. Therefore,
activated Akt in TM4SF5-expressing cells may also facilitate nuclear
translocation of cyclin D1. Meanwhile, it is suggested that PI3K/Akt
signaling activity is essential but not sufﬁcient for nuclear localiza-
tion of cyclin D, and additional signaling activity is thus necessary
[32]. Cell adhesion to ECM is well-known to inﬂuence gene
regulation through Rho GTPase-mediated actin reorganization [33].
Rho GTPase activity is involved in nuclear accumulation of MAL, a
cofactor of transcription factor SRF (serum response factor) [34]. On
the other hand, depolymerization of actin ﬁlaments causes nuclear
translocation of NCK, a potent N-WASP activator [35]. Therefore,
abnormal organization of actin cytoskeleton can also cause nuclear
translocation of certain proteins. Likewise, aberrant actin organiza-
tion by inactive RhoA in TM4SF5 expressing cells [13] may also be
involved in facilitated translocations of cyclin D1 and CDK4 into the
nucleus.
Cancer cells appear to use membrane receptor-mediated regulation
of actin organization to alter cell–cell contacts [47] and perturb contact
inhibition. Such aberrant actin organizationmay be caused by abnormal
regulation of RhoA GTPases. This study shows that RhoA/ROCK
signaling activity can affect cell cycle progression. It was previously
shown that RhoA activity blocks the Rac1/CDC42-mediated inductionof
cyclin D1 in early G1 phase and at the same time sustains growth factor
receptor/integrin-mediatedErk1/2 activity to cause cyclinD1 induction
Fig. 5. Regulation of p27Kip1 expression inhibited the TM4SF5-mediated acceleration of
G1/S phase progression. SNU449Cp (Cp) and SNU449Tp (Tp) cells were infected with
adenovirus containing control sequence or siRNA against p27Kip1 (A and B), during
serum starvation for 24 h. Then, incubation with 10% FBS-containing culture media was
performed for the indicated time periods. After the incubation, the cells were harvested
for standardWestern blots for the indicated molecules (A) or cell cycle analysis via ﬂow
cytometry after DNA staining with propidium iodide, as explained in the Materials and
methods (B). * depicts a signiﬁcant difference (p≤0.05) between a closed and an open
symbol for a cell cycle phase at a time point (i.e.,□ versus■). Data values from at least 3
isolated experiments were calculated to obtain mean±standard deviation values for
graphic presentations. Data shown represents three isolated experiments.
Fig. 6. Regulation of RhoA/ROCK signaling activity inhibited the TM4SF5-mediated
acceleration of G1/S phase progression. SNU449Cp (Cp) and SNU449Tp (Tp) cells were
infected with control or active RhoA (63L) adenovirus (A and B) or treated with Y27632
(a speciﬁc ROCK inhibitor, C and D) at different concentrations in the presence (C, top)
or absence (C, bottom) of serum for 24 h. Then, incubation with 10% FBS-containing
culture media was performed for the indicated time periods (C, bottom). After the
incubation, the cells were harvested for standard Western blots for the indicated
molecules (A and C) or ﬂow cytometry analysis (B and D) to examine cell cycle
population. * depicts a signiﬁcant difference (p≤0.05) between a closed and an open
symbol for a cell cycle phase at a time point (i.e.,□ versus■). Data values from at least 3
different experiments were calculated to get mean±standard deviation values for
graphic presentations. Data shown represents three independent experiments.
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and RhoA inactivation [13] appeared to shorten G1 phase or accelerate
G1/S phase progression in this study. Activation of RhoA in TM4SF5-
expressing cells resulted in a retarded progression of cells into S phase,
and inactivation of ROCK in TM4SF5-null cells enhanced S phase entry.
Therefore, in addition to cellmigrationand invasion [49], RhoA signaling
may be important for the regulation of cell proliferation via modulation
of presumablyG1phase duration,wheremalignant transformationmay
involve cytosolic p27Kip1 stabilization that is mediated by actions of
membrane receptors like TM4SF5.
p27Kip1 has been shown to accumulate in the cytosol of diverse
tumor tissues [36,37], including colon [38], Barrett's associated
adenocarcinoma [39], glioma [40], thyroid tumors [41], breast cancer
[42], and hepatocarcinoma [13]. However, it is unclear how cytosolic
p27Kip1 causes tumorigenesis [37]. This study also reveals how
cytosolic p27Kip1 can play a role in tumorigenesis, especially in
terms of cell cycle regulation. As a cyclin-dependent kinase inhibitor
(CKI), p27Kip1 in the nucleus inhibits G1 phase CDK/cyclin complex
formation and activity [43]. p27Kip1 is translocated into the cytosol
after Ser10 phosphorylation by Akt or KIS [22,37,44]. Cytosolic p27Kip1
interacts with RhoA to block RhoA activation by Rho GEF and causes
actin reorganization [45,46]. In cells and HCC tissues expressing
TM4SF5, both p27Kip1 mRNA and protein levels are stabilized and
signiﬁcantly accumulate in the cytosol [13]. TM4SF5 expression
mediates EMT important for TM4SF5-mediated roles in malignant
growth and TM4SF5-mediated EMT correlates with aberrant reorga-
nization of cortical actin [13,47]. Therefore, TM4SF5-mediated
cytosolic p27Kip1 may play roles in multilayer growth via loss of
contact inhibition and accelerated G1/S phase progression.Acknowledgements
This work was supported by the Korea Science and Engineering
Foundation (KOSEF) grant funded by the Korean government (MEST)
(CPMDRC, R13-2007-019-00000-0 to SHK), (Research Program for
New Drug Target Discovery through the NRF of Korea funded by
Ministry of Education, Science and Technology, 2007-03536 and Cell
Dynamics Research Center, R11-2007-007-01004-0 to JW Lee).Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.bbamcr.2010.04.001.References
[1] I. Stamenkovic, Extracellular matrix remodelling: the role of matrix metallopro-
teinases, J. Pathol. 200 (2003) 448–464.
[2] L.A. Liotta, C.N. Rao, U.M. Wewer, Biochemical interactions of tumor cells with the
basement membrane, Annu. Rev. Biochem. 55 (1986) 1037–1057.
[3] W. Guo, F.G. Giancotti, Integrin signalling during tumour progression, Nat. Rev.
Mol. Cell Biol. 5 (2004) 816–826.
[4] P.J. Reddig, R.L. Juliano, Clinging to life: cell to matrix adhesion and cell survival,
Cancer Metastasis Rev. 24 (2005) 425–439.
982 H. Kim et al. / Biochimica et Biophysica Acta 1803 (2010) 975–982[5] N. Gavert, A. Ben-Ze'ev, Epithelial–mesenchymal transition and the invasive
potential of tumors, Trends Mol. Med. 14 (2008) 199–209.
[6] S.Y. Sung, C.L. Hsieh, D. Wu, L.W. Chung, P.A. Johnstone, Tumor microenvironment
promotes cancer progression, metastasis, and therapeutic resistance, Curr. Probl.
Cancer 31 (2007) 36–100.
[7] B. Geiger, J.P. Spatz, A.D. Bershadsky, Environmental sensing through focal
adhesions, Nat. Rev. Mol. Cell Biol. 10 (2009) 21–33.
[8] M. Guarino, B. Rubino, G. Ballabio, The role of epithelial–mesenchymal transition
in cancer pathology, Pathology 39 (2007) 305–318.
[9] G.I. Evan, K.H. Vousden, Proliferation, cell cycle and apoptosis in cancer, Nature
411 (2001) 342–348.
[10] M.D. Wright, J. Ni, G.B. Rudy, The L6 membrane proteins—a new four-
transmembrane superfamily, Protein Sci. 9 (2000) 1594–1600.
[11] F. Muller-Pillasch, C.Wallrapp, U. Lacher, H. Friess, M. Buchler, G. Adler, T.M. Gress,
Identiﬁcation of a new tumour-associated antigen TM4SF5 and its expression in
human cancer, Gene 208 (1998) 25–30.
[12] L. Pascual-Le Tallec, E. Dulmet, X. Bertagna, Y. de Keyzer, Identiﬁcation of genes
associated with the corticotroph phenotype in bronchial carcinoid tumors, J. Clin.
Endocrinol. Metab. 87 (2002) 5015–5022.
[13] S.A. Lee, S.Y. Lee, I.H. Cho, M.A. Oh, E.S. Kang, Y.B. Kim, W.D. Seo, S. Choi, J.O. Nam, M.
Tamamori-Adachi, S. Kitajima, S.K. Ye, S. Kim, Y.J. Hwang, I.S. Kim, K.H. Park, J.W. Lee,
Tetraspanin TM4SF5 mediates loss of contact inhibition through epithelial–mesen-
chymal transition in human hepatocarcinoma, J. Clin. Invest. 118 (2008) 1354–1366.
[14] C.S. Stipp, T.V. Kolesnikova, M.E. Hemler, Functional domains in tetraspanin
proteins, Trends Biochem. Sci. 28 (2003) 106–112.
[15] S.-Y. Lee, Y.T. Kim, M.-S. Lee, Y.-B. Kim, E. Chung, S. Kim, J.W. Lee, Focal adhesion
and actin organization by a cross-talk of TM4SF5with integrinα2 are regulated by
serum treatment, Exp. Cell Res. 312 (2006) 2983–2999.
[16] S. Choi, S.A. Lee, T.K. Kwak, H.J. Kim, M.J. Lee, S.K. Ye, S.H. Kim, S. Kim, J.W. Lee,
Cooperation between integrin α5 and tetraspan TM4SF5 regulates VEGF-
mediated angiogenic activity, Blood 113 (2009) 1845–1855.
[17] S.A. Lee, Y.M. Kim, T.K. Kwak, H.J. Kim, S. Kim, S.H. Kim, K.H. Park, M. Cho, J.W. Lee,
The extracellular loop 2 of TM4SF5 inhibits integrin α2 on hepatocytes under
collagen type I environment, Carcinogenesis 30 (2009) 1872–1879.
[18] J. Erenpreisa, M.S. Cragg, Cancer: a matter of life cycle? Cell Biol. Int. 31 (2007)
1507–1510.
[19] J.R. Nevins, The Rb/E2F pathway and cancer, Hum. Mol. Genet. 10 (2001) 699–703.
[20] C. Gutierrez, E. Ramirez-Parra, M.M. Castellano, J.C. del Pozo, G(1) to S transition:
more than a cell cycle engine switch, Curr. Opin. Plant Biol. 5 (2002) 480–486.
[21] H.-P. Kim, T.-Y. Kim, M.-S. Lee, H.-S. Jong, T.-Y. Kim, J. Weon Lee, Y.-J. Bang, TGF-
[beta]1-mediated activations of c-Src and Rac1 modulate levels of cyclins and
p27Kip1 CDK inhibitor in hepatoma cells replated on ﬁbronectin, BBA - Mol. Cell
Res. 1743 (2005) 151–161.
[22] J. Liang, J. Zubovitz, T. Petrocelli, R. Kotchetkov, M.K. Connor, K. Han, J.H. Lee, S.
Ciarallo, C. Catzavelos, R. Beniston, E. Franssen, J.M. Slingerland, PKB/Akt
phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated
G1 arrest, Nat. Med. 8 (2002) 1153–1160.
[23] C. Albanese, J. Johnson, G. Watanabe, N. Eklund, D. Vu, A. Arnold, R.G. Pestell,
Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter
through distinguishable regions, J. Biol. Chem. 270 (1995) 23589–23597.
[24] M.-S. Lee, T.Y. Kim, Y.-B. Kim, S.-Y. Lee, S.-G. Ko, H.-S. Jong, T.-Y. Kim, Y.-J. Bang, J.
W. Lee, The signaling network of transforming growth factor β1, protein kinase C
δ, and integrin underlies the spreading and invasiveness of gastric carcinoma cells,
Mol. Cell. Biol. 25 (2005) 6921–6936.
[25] S. Meloche, J. Pouyssegur, The ERK1/2mitogen-activated protein kinase pathway as
amaster regulator of the G1- to S-phase transition, Oncogene 26 (2007) 3227–3239.
[26] T. Ueta, M. Ikeguchi, Y. Hirooka, N. Kaibara, T. Terada, β-catenin and cyclin D1
expression in human hepatocellular carcinoma, Oncol. Rep. 9 (2002) 1197–1203.[27] M.F. Roussel, Regulation of cell cycle entry and G1 progression by CSF-1, Mol.
Reprod.Dev. 46 (1997) 11–18.
[28] M.F. Olson, Contraction reaction: mechanical regulation of Rho GTPase, Trends
Cell Biol. 14 (2004) 111–114.
[29] Y.-B. Kim, J. Yu, S.-Y. Lee, M.-S. Lee, S.-G. Ko, S.-K. Ye, H.-S. Jong, T.-Y. Kim, Y.-J. Bang, J.
W. Lee, Cell adhesion status-dependent histone acetylation is regulated through
intracellular contractility-related signaling activities, J. Biol. Chem. 280 (2005)
28357–28364.
[30] S. Ortega, M. Malumbres, M. Barbacid, Cyclin D-dependent kinases, INK4
inhibitors and cancer, Biochim. Biophys. Acta 1602 (2002) 73–87.
[31] A.B. Gladden, J.A. Diehl, Location, location, location: the role of cyclin D1 nuclear
localization in cancer, J. Cell. Biochem. 96 (2005) 906–913.
[32] M. Yamamoto, S. Tamakawa, M. Yoshie, Y. Yaginuma, K. Ogawa, Neoplastic
hepatocyte growth associated with cyclin D1 redistribution from the cytoplasm to
the nucleus in mouse hepatocarcinogenesis, Mol. Carcinog. 45 (2006) 901–913.
[33] R.S. Gieni, M.J. Hendzel, Actin dynamics and functions in the interphase nucleus:
moving toward an understanding of nuclear polymeric actin, Biochem. Cell Biol.
87 (2009) 283–306.
[34] F. Miralles, G. Posern, A.I. Zaromytidou, R. Treisman, Actin dynamics control SRF
activity by regulation of its coactivator MAL, Cell 113 (2003) 329–342.
[35] B.E. Kremer, L.A. Adang, I.G. Macara, Septins regulate actin organization and cell-
cycle arrest through nuclear accumulation of NCK mediated by SOCS7, Cell 130
(2007) 837–850.
[36] G. Viglietto, M.L. Motti, A. Fusco, Understanding p27kip1 deregulation in cancer:
down-regulation or mislocalization, Cell Cycle 1 (2002) 394–400.
[37] I.M. Chu, L. Hengst, J.M. Slingerland, The Cdk inhibitor p27 in human cancer: prognostic
potential and relevance to anticancer therapy, Nat. Rev. Cancer 8 (2008) 253–267.
[38] M. Ciaparrone, H. Yamamoto, Y. Yao, A. Sgambato, G. Cattoretti, N. Tomita, T.
Monden, H. Rotterdam, I.B. Weinstein, Localization and expression of p27KIP1 in
multistage colorectal carcinogenesis, Cancer Res. 58 (1998) 114–122.
[39] S.P. Singh, J. Lipman, H. Goldman, F.H. Ellis Jr., L. Aizenman, M.G. Cangi, S.
Signoretti, D.S. Chiaur, M. Pagano, M. Loda, Loss or altered subcellular localization
of p27 in Barrett's associated adenocarcinoma, Cancer Res. 58 (1998) 1730–1735.
[40] S. Nakasu, M. Nakajima, J. Handa, Anomalous p27kip1 expression in a subset of
malignant gliomas, Brain Tumor Pathol. 16 (1999) 17–21.
[41] G. Baldassarre, B. Belletti, P. Bruni, A. Boccia, F. Trapasso, F. Pentimalli, M.V. Barone,
G. Chiappetta, M.T. Vento, S. Spiezia, A. Fusco, G. Viglietto, Overexpressed cyclin
D3 contributes to retaining the growth inhibitor p27 in the cytoplasm of thyroid
tumor cells, J. Clin. Invest. 104 (1999) 865–874.
[42] G. Viglietto, M.L. Motti, P. Bruni, R.M. Melillo, A. D'Alessio, D. Califano, F. Vinci, G.
Chiappetta, P. Tsichlis, A. Bellacosa, A. Fusco, M. Santoro, Cytoplasmic relocaliza-
tion and inhibition of the cyclin-dependent kinase inhibitor p27Kip1 by PKB/Akt-
mediated phosphorylation in breast cancer, Nat. Med. 8 (2002) 1136–1144.
[43] M.H. Lee, H.Y. Yang, Negative regulators of cyclin-dependent kinases and their
roles in cancers, Cell. Mol. Life Sci. 58 (2001) 1907–1922.
[44] N. Fujita, S. Sato, K. Katayama, T. Tsuruo, Akt-dependent phosphorylation of
p27Kip1 promotes binding to 14-3-3 and cytoplasmic localization, J. Biol. Chem.
277 (2002) 28706–28713.
[45] A. Besson, M. Gurian-West, A. Schmidt, A. Hall, J.M. Roberts, p27Kip1 modulates cell
migration through the regulation of RhoA activation, GenesDev. 18 (2004) 862–876.
[46] A. Besson, S.F. Dowdy, J.M. Roberts, CDK inhibitors: cell cycle regulators and
beyond, Dev. Cell 14 (2008) 159–169.
[47] R.J. Muschel, A. Gal, Tetraspanin in oncogenic epithelial–mesenchymal transition,
J. Clin. Invest. 118 (2008) 1347–1350.
[48] C.F.Welsh, K. Roovers, J. Villanueva, Y. Liu,M.A. Schwartz, R.K. Assoian, Timing of cyclin
D1 expression within G1 phase is controlled by Rho, Nat. Cell Biol. 3 (2001) 950–957.
[49] R. Karlsson, E.D. Pedersen, Z. Wang, C. Brakebusch, Rho GTPase function in
tumorigenesis, Biochim. Biophys. Acta 1796 (2009) 91–98.
